Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-
Clinical Trials
Related News

Risperidone vs. Paroxetine for Panic Attacks

First Posted Date
2005-09-21
Last Posted Date
2012-10-22
Lead Sponsor
Beth Israel Medical Center
Target Recruit Count
90
Registration Number
NCT00206765
Locations
🇺🇸

Beth Israel Medical Center, New York, New York, United States

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

First Posted Date
2005-09-21
Last Posted Date
2013-01-14
Lead Sponsor
AstraZeneca
Target Recruit Count
1098
Registration Number
NCT00206102
Locations
🇺🇸

Research Site, Richmond, Virginia, United States

Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia

Not Applicable
Completed
Conditions
Schizophrenia
Interventions
Drug: zuclopenthixol
Drug: risperidone
First Posted Date
2005-09-21
Last Posted Date
2011-09-19
Lead Sponsor
Birte Glenthoj
Target Recruit Count
56
Registration Number
NCT00206960
Locations
🇩🇰

University of Copenhagen, Dept. F, Bispebjerg Hospital, Copenhagen NV, Denmark

🇩🇰

Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital, Hvidovre, Denmark

🇩🇰

University of Copenhagen, Dept. of Psychiatry E, Bispebjerg Hospital, Copenhagen NV, Denmark

and more 3 locations

A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-21
Last Posted Date
2010-11-19
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
273
Registration Number
NCT00210691

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

First Posted Date
2005-09-21
Last Posted Date
2007-12-13
Lead Sponsor
Creighton University
Target Recruit Count
20
Registration Number
NCT00208143
Locations
🇺🇸

Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

Phase 4
Completed
Conditions
Substance Abuse
Bipolar Depression
First Posted Date
2005-09-20
Last Posted Date
2007-03-19
Lead Sponsor
Tuscaloosa Research & Education Advancement Corporation
Target Recruit Count
30
Registration Number
NCT00203528
Locations
🇺🇸

Tuscaloosa Research & Education Advancement Corporation, Tuscaloosa, Alabama, United States

Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates

Not Applicable
Terminated
Conditions
Psychosis
Aggression
First Posted Date
2005-09-20
Last Posted Date
2006-10-13
Lead Sponsor
University of Connecticut
Registration Number
NCT00203775
Locations
🇺🇸

University of connecticut health center, Farmington, Connecticut, United States

Use of Risperidone in ECT for Treatment Resistant Depression

Phase 4
Terminated
Conditions
Major Depression
First Posted Date
2005-09-20
Last Posted Date
2006-05-18
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
45
Registration Number
NCT00203723
Locations
🇺🇸

UCLA Npi&H, Los Angeles, California, United States

Metabolic Effects of Antipsychotics in Children

First Posted Date
2005-09-20
Last Posted Date
2018-06-15
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
144
Registration Number
NCT00205699
Locations
🇺🇸

Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

Phase 4
Completed
Conditions
Borderline Personality Disorder
First Posted Date
2005-09-20
Last Posted Date
2021-06-10
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
20
Registration Number
NCT00204347
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy